

FROM
3rd TO 4th OCTOBER
2024

13th ANNUAL ACUTE LEUKEMIA MEETING

IN PERSON & VIRTUAL EVENT

DIRECTOR

Dr. Adolfo de la Fuente

MD Anderson Cancer Center Madrid, Spain

www.mdanderson.es/cursoleucemia

Scientific Committee

Dr. Gabriela Rodríguez

Hospital General Universitario Gregorio Marañón

Dr. María Luz Amigo

Hospital General Universitario Morales Meseguer, Murcia, Spain

Dr. Valentín García-Gutiérrez

Hospital Universitario Ramón y Cajal, Madrid, Spain

Dr. Guillermo García-Manero

MD Anderson Cancer Center, Houston, USA

Dr. Mayte Olave

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Dr. Belén Vidriales

Hospital Clínico Universitario de Salamanca, Spain

Dr. Mar Tormo

Hospital Clínico Universitario de Valencia, Spain

Dr. David Valcárcel

*Hospital valle de Hebron Barcelona. Institute of Oncology,
Hospital Quirónsalud Barcelona, Spain*

Dr. Claudio Cerchione

IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST, Meldola, Italy

Dr. Naval Daver

MD Anderson Cancer Center, Houston, USA

Dr. Alessandro Isidori

Marche Nord Hospital, Pesaro, Italy

Dr. Elias Jabbour

MD Anderson Cancer Center, Houston, USA

Ambassadors

Dr. Virginia Abello

*Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo,
Bogotá, Colombia*

Dr. Breno Moreno de Gusmão

Benecência Portuguesa de São Paulo, São Paulo, Brasil

Dr. Marta Rivas

Hospital Universitario Austral, Buenos Aires, Argentina

Dr. Alejandra Romero

Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile

Evaluation Committee

Dr. M^a Luz Amigo Lozano

Hospital General Univ. Morales Meseguer, Murcia

Dr. Adolfo de la Fuente

MD Anderson Cancer Center Madrid

Dr. Ángela Figuera

Hospital de La Princesa, Madrid, Spain

Dr. Mayte Olave

Hospital Clínico de Zaragoza

Dr. Gabriela Rodríguez

Hospital General Univ. Gregorio Marañón, Madrid

Dr. Mar Tormo

Hospital Clínico Universitario de Valencia, Spain

Dr. David Valcárcel

Hospital Univ. Vall d'Hebron, Institute of Oncology, Barcelona

Dr. María Belén Vidriales

Hospital Clínico Universitario de Salamanca, Spain

09:00 - 09:10

Welcome

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

09:10 - 10:20

Session 1

Myelodysplastic syndromes I

Chairs:

Dr. David Valcárcel, *Hospital Universitario Vall d'Hebron, Institute of Oncology, Hospital Quirónsalud Barcelona, Spain*

Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

Dr. Breno Moreno de Gusmão, *Benecência Portuguesa de São Paulo, São Paulo, Brasil*

09:10 - 09:30

Germline predisposition: Clinical relevance, who to study? Impact on patient management

Dr. Julia Montoro, *Hospital Universitario Vall d'Hebron, Barcelona, Spain*

09:30 - 09:50

Low- risk MDS, looking to the future

Dr. Ana Alfonso, *Clínica Universidad de Navarra, Pamplona, Spain*

09:50 - 10:10

Targeted Approaches in MDS

Dr. Lionel Adès, *Hôpital Saint-Louis, Paris, France*

10:10 - 10:20

Discussion

10:20 - 10:50

Meet the Expert 1

Management of myelofibrosis in 2024

Chairs:

Dr. María Luz Amigo, *Hospital General Universitario Morales Meseguer, Murcia, Spain*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

Dr. Virginia Abello, *Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia*

10:20 - 10:40

Dr. Valentín García-Gutiérrez, *Hospital Universitario Ramón y Cajal, Madrid, Spain*

10:40 - 10:50

Discussion

10:50 - 11:20

Coffee break

11:20 - 12:35

Session 2

Immunotherapy

Chairs: Dr. Gabriela Rodríguez, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*
Dr. Valentín García-Gutiérrez, *Hospital Universitario Ramón y Cajal, Madrid, Spain*
Dr. Marta Rivas, *Hospital Universitario Austral, Buenos Aires, Argentina*

11:20 - 11:40

Immunotherapy a history of failures

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

11:40 - 12:00

Immunotherapy a history of successes

Dr. Antonio Curti, *Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola, Bologna, Italy*

12:00 - 12:20

Targeting CD123 and CD33 in AML: Antibodies and cell therapy approaches

Dr. Naval Daver, *MD Anderson Cancer Center, Houston, USA*

12:20 - 12:35

Discussion

12:35 - 14:10

Session 3

AML redefining risks and opportunities

Chairs: Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*
Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*
Dr. Ángela Figuera, *Hospital de La Princesa, Madrid, Spain*

12:35 - 12:55

Redefining fit and unfit. Criteria

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

12:55 - 13:15

Transplantation in seniors over 70 years

Dr. María Queralta Salas, *Hospital Clínic de Barcelona, Spain*

13:15 - 13:35

Tips and tricks oral azacitidine as maintenance in AML

Dr. María Teresa Voso, *University of Rome Tor Vergata, Roma, Italy*

13:35 - 13:55

Update on antibiotherapy and antifungals in/for the haematological patient

Dr. Rafael de la Cámara, *Hospital Universitario de La Princesa, Madrid, Spain*

13:55 - 14:10

Discussion

14:10 - 15:10

Lunch

14:10 - 14:40

Meet the Expert 2

Challenges in the treatment of patients with CLL in 2024

Chair:

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

Dr. Breno Moreno de Gusmão, *Benecência Portuguesa de São Paulo, São Paulo, Brasil*

Dr. Virginia Abello, *Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia*

14:10 - 14:30

Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*

14:30 - 14:40

Discussion

15:10 - 16:25

Session 4

AML II - Target therapies

Chairs:

Dr. María Belén Vidriales, *Hospital Clínico Universitario de Salamanca, Spain*

Dr. María Luz Amigo, *Hospital General Universitario Morales Meseguer, Murcia, Spain*

Dr. Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile*

15:10 - 15:30

IDHA inhibitors in AML in 2024 and now what?

Dr. Blanca Boluda, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

15:30 - 15:50

Menin inhibitors

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

15:50 - 16:10

Targeting TP 53 where are we now?

Dr. Thomas Cluzeau, *Hospital Center Universitaire de Nice, France*

16:10 - 16:25

Discussion

16:25 - 18:00

Session 5**Lymphoblastic**

Chairs:

Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*Dr. Breno Moreno de Gusmão, *Benecência Portuguesa de São Paulo, São Paulo, Brasil*Dr. Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile*

16:25 - 16:45

Management of the elderly patient with ALLDr. Anna Torrent, *Hospital Universitario Germans Trias i Pujol, Barcelona, Spain*

16:45 - 17:45

Discussion: alloSCT for Ph+ ALL to do or not to do?**YES** - Dr. Josep Maria Ribera, *Instituto de Investigación contra la Leucemia Josep Carreras, Barcelona, Spain***NO** - Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*

17:45 - 18:00

Discussion

18:00 - 18:30

Coffee break

18:30 - 20:30

Session 6**AML I - Targeting FLT3 in AML**

Chairs:

Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*Dr. Marta Rivas, *Hospital Universitario Austral, Buenos Aires, Argentina*

18:30 - 18:50

AML diagnosis WHO and ICC 2022Dr. Irene Sánchez-Vadillo, *Hospital Universitario La Paz, Madrid, Spain*

18:50 - 19:10

FLT3 AML where do we come from: focus on R/R FLT3 AMLDr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

19:10 - 19:30

Optimal approaches to frontline fit FLT3 ITD AML: Which FLT3 inhibitor is the best?Dr. Alexander Perl, *Abramson Cancer Center, Pennsylvania, USA*

19:30 - 19:50

Mechanisms of resistance to FLT3 inhibitors and building novel combinations to overcome resistanceDr. Naval Daver, *MD Anderson Cancer Center, Houston, USA*

19:50 - 20:10

FLT3 inhibitors for FLT3 wild type AMLDr. Blanca Boluda, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

20:10 - 20:30

Discussion

08:00 - 09:15

Session 7**Biology and diagnostics**

Chairs:

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*Dr. Ángela Figuera, *Hospital de La Princesa, Madrid, Spain*

08:00 - 08:20

Clonal haematopoiesis and leukaemogenesisDr. Klaus Metzeler, *Leipzig University, Leipzig, Germany*

08:20 - 08:40

Genetic alterations in AML and MDS-AR - the same or different?Dr. Rosa Ayala, *Hospital Universitario 12 de Octubre, Madrid, Spain*

08:40 - 09:00

Diagnosis and classification of ALL in 2024Dr. María Luz Amigo, *Hospital General Universitario Morales Meseguer, Murcia, Spain*

09:00 - 09:15

Discussion

09:15 - 10:05

Session 8**Myelodysplastic syndromes II**

Chairs:

Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*Dr. Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile*

09:15 - 09:35

Response criteria in MDSDr. David Valcárcel, *Hospital Universitario Vall d'Hebron, Institute of Oncology, Hospital Quirónsalud, Barcelona, Spain*

09:35 - 09:55

High-risk treatment: Towards total oral therapyDr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

09:55 - 10:05

Discussion

10:05 - 10:35

Coffee break

10:35 - 11:50

Session 9**My day to day life at the AML**

Chairs: Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA
Dr. María Belén Vidriales, Hospital Clínico Universitario de Salamanca, Spain
Dr. Marta Rivas, Hospital Universitario Austral, Buenos Aires, Argentina

10:35 - 10:55

Favourable risk AML. Treatment: transplantation autologous vs CT?

Dr. Josefina Serrano, Hospital Universitario Reina Sofía, Córdoba, Spain

10:55 - 11:15

AML with FLT3 mutations - really intermediate risk?

Dr. Gabriela Rodríguez, Hospital General Universitario Gregorio Marañón, Madrid, Spain

11:15 - 11:35

What do I offer to my patient in RC1, maintenance or allogeneic transplantation?

Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain

11:35 - 11:50

Discussion

11:50 - 12:55

WORKSHOP 1**Blastic plasmacytoid dendritic cell neoplasm (BPDCN AML Study and diagnosis)**

Chairs: Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA
Dr. Claudio Cerchione, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy
Dr. Virginia Abello, Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia
Dr. Alejandra Romero, Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile

11:50 - 12:10

Challenges in the diagnosis of BPDCN

Dr. María Belén Vidriales, Hospital Clínico Universitario de Salamanca, Spain

12:10 - 12:30

Management of the patient with BPDCN

Dr. Naveen Pemmaraju, MD Anderson Cancer Center, Houston, USA

12:30 - 12:40

Clinical case

Dr. Marta Rivas, Hospital Universitario Austral, Buenos Aires, Argentina

12:40 - 12:55

Conclusions

12:55 - 14:05

Session 10**The relevance of a precise diagnosis in the mIDH1 AML unfit patient for an optimal frontline treatment**

Chair: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
Dr. Ángela Figuera, Hospital de La Princesa, Madrid, Spain

12:55 - 13:05

Testing in time: The importance of molecular testing time frames

Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain

13:05 - 13:15

How do you manage all the complexities of new treatment choices in the mIDH1 AML patient ineligible for intensive chemotherapy?

Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain

13:15 - 13:25

Experience in real world setting with targeted therapies

Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA

13:25 - 13:35

Clinical case I

Dr. Pilar Herrera, Hospital General Univ. Gregorio Marañón, Madrid

13:35 - 13:45

Clinical case II

Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy

13:45 - 14:05

Case based discussion

14:05-15:05

Lunch

15:05 - 16:00

Session 11**Intensive approach to AML**

Chairs: Dr. Gabriela Rodríguez, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Dr. Claudio Cerchione, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy
Dr. Virginia Abello, Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia
Dr. Alejandra Romero, Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile

15:05 - 15:25

High risk AML the big picture and long term follow up

Dr. Christina Rautenberg, Essen University Hospital, Stem Cell Transplantation, Essen, Germany

15:25 - 15:45

Impact of intensive chemotherapy on the intestinal mucosa

Dr. Luigina Romani, University of Perugia, Italy

15:45 - 16:00

Discussion

16:00 - 17:15

Session 12**AML III- Targeting apoptosis**

Chairs: Dr. David Valcárcel, *Hospital Universitario Vall d'Hebron, Institute of Oncology, Hospital Quirónsalud, Barcelona, Spain*

Dr. Naval Daver, *MD Anderson Cancer Center, Houston, USA*

Dr. Ángela Figuera, *Hospital de La Princesa, Madrid, Spain*

16:00 - 16:20

How to optimize the use of HMA+venetoclax in the unfit patient in healthcare practice

Dr. Ofir Wolach, *Davidoff Cancer Centre, Petaj Tikva, Israel*

16:20 - 16:40

Combinations of venetoclax with chemotherapy in AML treatment

Dr. Rebeca Rodríguez, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

16:40 - 16:50

Clinical case

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

16:50 - 17:15

Discussion

17:15 - 17:30

Coffee break

17:30 - 18:50

Session 13**MRD in Acute Leukemia**

Chairs: Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

17:30 - 17:50

B cell Acute Lymphoblastic Leukemia MRD based algorithm

Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*

17:50 - 18:10

Value of MRD in non-intensively treated AML patients

Dr. María Belén Vidriales, *Hospital Clínico Universitario de Salamanca, Spain*

18:10 - 18:30

Management of AML with MRD+ following allogeneic transplantation

Dr. David Valcárcel, *Hospital Universitario Vall d'Hebron Institute of Oncology, Hospital Quirónsalud, Barcelona, Spain*

18:30 - 18:50

Discussion

18:50 - 19:00

Clinical Cases Award Ceremony

Friday

4th
OCTOBER
2024

19:00 - 19:20

Special session

Introducing SOHO

The Society of Hematologic Oncology (SOHO)

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

Dr. Claudio Cerchione, *IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy*

Dr. Pau Montesinos, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*

Dr. Naval Daver, *MD Anderson Cancer Center, Houston, USA*

Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

19:20 - 19:30

Closing

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

Sponsors

PLATINUM

abbvie



Daichi-Sankyo

SERVIER
moved by you

GOLD

 Bristol Myers Squibb™



MENARINI
group

Stemline

A Menarini Group Company

SILVER

 astellas



Incyte

 **Jazz** Pharmaceuticals

 **NOVARTIS**



Otsuka

 **Pfizer**

BRONZE

AstraZeneca 



BeiGene

CURIS

RYYU
THERAPEUTICS



SHIONOGI

COLABORATORS

AMGEN

Organized By

MD Anderson
~~Cancer Center~~
Madrid • España

MD Anderson
~~Cancer Center~~
Fundación • España

Accreditation

Credits requested from the Continuing Education Commission
of Health Professions of the Community of Madrid

Auspice

With scientific endorsement



Sociedad Española de
Hematología y Hemoterapia

Venue

MD Anderson Cancer Center Spain Foundation Auditorium
C/ Arturo Soria, 270, 28033, Madrid

Technical Secretary

doctaforum

(+34) 91 372 02 03
e-mail: cursoleucemia@doctaforum.com
www.mdanderson.es/cursoleucemia